



Synthesis, characterization, antibacterial, antioxidant and antiinflammatory activities of new 4-Aryl-2-amino-6-(4-hydroxy coumarin-3yl) pyridine-3-carbonitriles derivatives

Naceur HAMDI^{1,2}

- ¹ Chemistry department, College of Science and Arts, Al-Rass, P.O. Box 53, Qassim University, Buraidah 51477, Saudi Arabia
- ² Higher Institute of Environmental Science and Technologies (HIEST-Borj Cedria, Tunisia), University of Carthage, Touristic Road of Soliman, BP 95, Hammam-Lif 2050, Tunisia

Email: naceur.hamdi@isste.rnu.tn

ABSTRACT

This study aimed for the synthesis of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** suitable for use as antibacterial, anti-oxidant and anti-inflammatory activities via a versatile, readily accessible 3-((2E)-3(aryl)prop-2-enoyl)-2H-chromen-2-one **3** which was prepared by refluxing 3-acetyl-4-hydroxycoumarin with aromatic aldehydes in chloroform in the presence of a catalytic amount of piperidine. Then the direct reaction of the obtained chalcones **3** with malonitrile in the presence of ammonium acetate in one step gave products **5** The structures of the new compounds **3-4** were confirmed by elemental analysis, IR, and multinuclear/multidimensional NMR spectroscopy (¹H, ¹³C-NMR, NOESY, HMBC) which allowed assignment of the complete network of proton and carbon atoms. Most of the new compounds **4** exhibit moderate antibacterial activity against Gram Negative bacterial strains (E. coli, K. pneumonia, S. typhi and S. flexneri). In addition, the compounds **4** were investigated for anti-oxidant activities by super oxide radical, DPPH (2,2-Diphenyl-1-picrylhydrazyl), and hydroxyl radical scavenging assays, where most of the compounds displayed significant antioxidant activities. Furthermore, these **4**-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** were evaluated for anti-inflammatory activity by indirect haemolytic and lipoxygenase inhibition assays where compounds revealed good activity.

Keywords

4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles; Antibacterial; Antioxidant; Anti-inflammatory; Synthesis

Council for Innovative Research

Peer Review Research Publishing System

Journal: Journal of Advances in Chemistry

Vol. 11, No. 1 editorjaconline@gmail.com www.cirjac.com



1. INTRODUCTION

The synthesis of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives **4** has attracted considerable attention of organic and medicinal chemists due to its wide usage in the field of drugs and pharmaceuticals with diverse biological activities like anticoagulant [1], antihypertensive [2], anti-inflammatory [3], antipsychotic [4], antidiabetic [5], antihelminthic [6] and antimicrobial activities [7, 8]. Nowadays various bacteria are found to resist classical antimicrobial agents [9]. Also, free radicals are highly reactive species generated endogenously with the involvement of oxygen in normal metabolic conditions and lack of antioxidant capacity of an organism may result in cancer development [10]. Besides, pathogen invasion, injuries and manifestation to chemicals results in inflammation which may leads to cancer, allergy, Alzheimer's disease, rheumatoid arthritis and diabetes mellitus [11].

Based on the literature survey on the pharmacological properties [12], we aimed to synthesize and characterize new 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles incorporating coumarin moiety. The chemical structures of the synthesized compounds **4** were determined by spectroscopic techniques. Their antibacterial, antioxidant activities and anti inflammaratory anti-inflammatory activity by indirect haemolytic and lipoxygenase were investigated.

2. EXPERIMENTAL

1. General

Reactions were monitored by thin layer chromatography (TLC) using precoated sheets of silica gel G/UV-254 of 0.25 mm thickness (Merck 60F254). The melting points were measured in Selaco melting point apparatus in an open capillary and are uncorrected. Elemental analysis (C, H, N) was performed using the CE-400 CHN elemental analyzer. Infrared spectra were recorded on Shimadzu FT-IR model 8300 spectrophotometer using KBr method. ¹H NMR spectra were recorded using Brucker 400 NMR spectrometer operating at 400 MHz using TMS as the internal standard and CDCl₃ as a solvent. Mass spectra were obtained using Agilant mass spectrometer in ESI mode. All chemicals were obtained from Aldrich, Fluka and Merck Chemicals.

2. Acetyl-4-hydroxycoumarin 2

To a solution of 4-hydroxy-2H-chromen-2-one (3.0 g, 1.86mmol) in acetic acid (16 ml) phosphorus oxychloride (5.6 ml) was added. The mixture was heated at reflux for 30 min. After cooling to room temperature, the precipitate which separated out was collected by filtration and recrystallized from ethanol to give 3-acetyl-4-hydroxy-2H-chromen-2-one as white needles. Yield 2.7 g (90%);Mp = 135 °C. IR spectrum, v cm⁻¹: 3185 (OH); 1705 (CO);1700 (O–CO lactone). ¹H NMR spectrum (CDCl₃) δ :2.72 (3H, s, CH₃); 7.98 (1H, s, H-5); 7.95 (1H, dd, ³J 7.8, 8.35, ⁴J 6.8, 1.2 Hz, H-8); 7.1–7.4 (2H, m, H-6 + H-7); 17.7 (1H, s, OH). ¹³C{¹H} NMR spectrum (CDCl₃): δ : 29.9 (CH₃); 178.5 (CO);159.8 (C-4); 154.6 (C-2); 101.3 (C-3); 115.0–136.0 (C_{arom}).

3. General procedure for the preparation of the coumarinic chalcones 3a-e

3-Acetyl-4-hydroxy-2*H* -chromen-2-one (0.031 mol) and the substituted aromatic aldehyde (0.03 mol) were dissolved in 30 mL of chloroform. A catalytic amount of piperidine (0.02 mol) was added and the reaction mixture was refluxed for 1.5 h. The chloroform was removed under vacuum and the residue was washed with methanol

3-((2E)-3(Phenyl)prop-2-enoyl)-2H-chromen-2-one: 3a

Yield 85 Yiled 85%; mp 265 °C. IR spectrum, v cm⁻¹: 1490 (C=O), 1728 (O-C-O), 1529 (C=C). ¹H NMR spectrum (CDCl₃) δ ppm: 6.5-8.3 (m,11H,H_{arom},H_{eth}); 18.25 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 116. 9 (C₃); 135.8 (C₂); 147.1(C₄); 134.7 (C_{ethyl}); 180.6 (CO); 135.9(C_{éthyl} 1); 131.4(C_{éthyl} 2); 126. 9 (C5); 125. 4 (C6); 128. 3 (C7); 128. 3 (C8); 135. 1 (C9); 126. 3 (C10); 128. 6 (C11); 127. 9 (C12); 128. 7 (C13); 126. 3 (C14).

3-((2E)-3(4-Fluorophenyl)prop-2-enoyl)-2H-chromen-2-one: 3b

Yiled 80%; mp 255°C. IR spectrum, v cm⁻¹: 1494 (C=O), 1716 (O-C-O), 1531 (C=C). ¹H NMR spectrum (CDCl₃, 400MHz) δ ppm: 6.51-8,21(m, 10H, H_{arom+éthyl}); 18. 4 (s, 1H, OH). ¹³C NMR spectrum (CDCl₃) δ ppm: 100.9 (C₃); 154.8 (C₂); 166.0 (C₄); 181.5 (CO); 136.2(C_{éthyl 1}); 131.5(C_{éthyl 2});126. 8 (C5); 125. 3 (C6); 128. 4 (C7); 129. 3 (C8); 135. 2 (C9); 126. 5 (C10); 128. 7 (C11); 127. 8 (C12); 128. 6 (C13); 126. 4 (C14). NMR ¹⁹F (CDCl₃, 400 MHz, t_{amb}) δ ppm: -107,8

3-((2E)-3(2, 5-Dimethylphenyl) prop-2-enoyl)-2H-chromen-2-one: 3c

Yield 75 %; mp 224°C. IR spectrum, v cm⁻¹: 1490 (C=O), 1720 (O-C-O), 1527 (C=C). ¹H NMR spectrum (CDCl₃,400 MHz) δ ppm: 2,41 (s,1H,CH₃),3,21 (s,3H,CH₃), 6,82-8,21 (m,9H,H_{arom+éthy});13.81 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm: 91. 4 (C₃); 135.8 (C₂); 161.4 (C₄); 139;1 (C_{éthyl}), 134.1 (C_{éthy2}); 126. 7 (C5); 125. 4 (C6); 128. 3 (C7); 128. 9 (C8); 135. 4 (C9); 126. 4 (C10); 127. 8 (C11); 127. 7 (C12); 128. 5 (C13); 126. 3(C14); 176.2 (CO).

3-((2E)-3(4-Methoxyphenyl) prop-2-enoyl)-2H-chromen-2-one: 3d

Yield 75 %; mp 194°C. IR spectrum, v cm⁻¹: 1494 (C=O), 1708 (O-C-O), 1595 (C=C). ¹H NMR spectrum (CDCl₃): δ ppm 3.84(s,3H,OCH₃); 6.92 (d,1H,CH); 8.25 (d,1H,CH); 7.25-8.08 (m,8H,H_{arom}); 18.05(s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 55.4 (OCH₃); 114.4 (C₃); 126. 8 (C5); 125. 2 (C6); 127. 9 (C7); 128. 8 (C8); 134. 8 (C9); 126. 3 (C10); 127. 7 (C11); 127. 5 (C12); 128. 4 (C13); 126. 2(C14); 135.6 (C₂); 147.5 (C₄); 162.4 (CO).



3-((2E)-3(4-Methoxyphenyl) prop-2-enoyl)-2H-chromen-2-one: 3e

Yield 75 %; mp 194°C. IR spectrum, v cm⁻¹: 1494 (C=O), 1708 (O-C-O), 1595 (C=C). ¹H NMR spectrum (CDCl₃): δ ppm 3.84(s,3H,OCH₃); 6.92 (d,1H,CH); 8.25 (d,1H,CH); 7.25-8.08 (m,8H,H_{arom}); 18.05(s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 55.4 (OCH₃); 114.4 (C₃); 126. 8 (C5); 125. 2 (C6); 127. 9 (C7); 128. 8 (C8); 134. 8 (C9); 126. 3 (C10); 127. 7 (C11); 127. 5 (C12); 128. 4 (C13); 126. 2(C14); 135.6 (C₂); 147.5 (C₄); 162.4 (CO).

3-((2E)-3(4-tollyl)prop-2-enoyl)-2H-chromen-2-one: 3f

Yield 72 %; mp 185°C. IR spectrum, v cm⁻¹: 1490 (C=O), 1715 (O-C-O), 1540 (C=C). ¹H NMR spectrum (CDCl₃) δ ppm: 2.1(s,3H,CH₃),7.1-8.6 (m,1OH, H_{arom+ethyl}); 18.4 (s, 1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm:22.6(CH₃), 98.7 (C₃); 151.8 (C₂); 178.7 (C₄); 182.5 (CO); 151.9(C_{ethyl 1}); 122.5(C_{ethyl 2}); 126. 7 (C5); 125. 3 (C6); 127. 8 (C7); 128. 7 (C8); 135. 2 (C9); 126. 4 (C10); 127. 6 (C11); 127. 4 (C12); 128. 5 (C13); 126. 3(C14).

4. General procedures for the preparation of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3yl) pyridine-3-carbonitriles derivative 4

To a mixture of coumarinic chalcones **3a–e** (1g, 5 mmol) in ethyl alcohol (20mL), malonitrile (0.33g, 5 mmol) and ammonium acetate (0.75g, 10 mmol) were added. The reaction mixture was refluxed for 7-9h. The obtained solid was filtered off, washed with absolute ethylalcohol and recrystallized from methyl alcohol to give the desired compounds

4-phenyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4a

Yield 86 %; mp 265 °C. IR spectrum, v cm⁻¹: 3264 (OH, br s), 3043 (NH), 2364 (CN), 1697 (C=O, a-pyrone), 1612 (C=O).1643 (C=N). ¹H NMR spectrum (CDCl₃) δ ppm: 6.3-8.6 (m,10H,H_{arom},H₂); 4.81 (s,2H,NH₂) ,18.25 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6(C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom}+ C_{coumarinic}), 160.4 (C₁). Anal. Calcd for C22H15O3N3: C, 71.536%; H, 4.093%, N, 11.376%, Found: C, 71.4%; H,4.093%, N, 11.3 %,

4-fluorophenyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4b

Yield 80 %; mp 265 °C. IR spectrum, v cm⁻¹: 3430 (OH, br s), 3187 (NH), 1675 (C=O, a-pyrone), 1603 (C=N).. ¹H NMR spectrum (CDCl₃) δ ppm: 6.2-8.3 (m,9H,H_{arom},H₂'); 4.81 (s,2H,NH₂),18.25 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄'); 122.6(C₂'); 151.9 (C₃'); 153.7 (C₅'), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom+Ccountrinic}), 160.4 (C₁). Anal. Calcd for C21H12O3N3F: C, 67.560%; H, 3.240%, N, 11.255%, F, 5.089% Found: C, 67.4%; H, 3.10%, N, 11.2%

4-2.5-phenyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4c

Yield 85 %; mp 265 °C. IR spectrum, v cm⁻¹: 3262 (OH, br s), 3098 (NH), 2354 (CN), 1696 (C=O, a-pyrone), 1658 (C=O). ¹H NMR spectrum (CDCl₃) δ ppm: 6.4-8.2 (m,8H,H_{arom},H₂); 4.81 (s,2H,NH₂), 2.1(s,CH₃), 2.3(s,CH₃) 18.25 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6(C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom}+ C_{coumarinic}), 160.4 (C₁). Anal. Calcd for C23H17O3N3: C, 72.052%; H, 4.469%, N, 10.960%, Found: C, 72.1%; H, 4.4%, N, 10.9%

4-Anisyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4d

Yield 80 %; mp 265 °C. IR spectrum, v cm⁻¹: 3316 (OH, br s), 3208, 3057 (NH2), 2206 (CN), 1680 (C=O, α-pyrone), 1643 (C=N). ¹H NMR spectrum (CDCl₃) δ ppm: 3.75(s, 3H, OCH₃), 6.4-8.2 (m,12H,H_{arom},H₂); 4.81 (s,2H,NH₂), 18.25 (s,1H,OH). ¹³C NMR spectrum (CDCl₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6(C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom}+ C_{coumarinic}), 160.4 (C₁). Anal. Calcd for C21H13O3N3: C, 70.980% ; H, 3.687%, N, 11.825%, Found: C, 70.9%; H, 3.6%, N, 11.8%,

4-nitrophenyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4e

Yield 85 %; mp 265 °C. IR spectrum, v cm⁻¹: 3392 (OH, br s), 3118, 3099 (NH2), 2210 (CN), 1722 (C=O, α -pyrone), 1653 (C=N). ¹H NMR spectrum (CDCl₃) δ ppm: 6.5-8.3 (m,9H,H_{arom},H₂); 18.25 (s,1H,OH), 4.81 (s,2H,NH₂). ¹³C NMR spectrum (CDCl₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6(C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom}+ C_{coumarinic}), 160.4 (C₁). Anal. Calcd for C22H15O4N3: C, 68.566% ; H, 3.923, N, 10.904%, Found: C, , 68.5%; H, 3.9%, N, 10.9%

4-tollyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4f

Yield 75 %; mp 265 °C. IR spectrum, v cm⁻¹: 3449 (OH, br s), 3057(NH), 2739 (CN), 1739 (C=O, a-pyrone), 1692 (C=O). ¹H NMR spectrum (CDCI₃) δ ppm: 6.4-8.2 (m,12H,H_{arom},H₂); à,2.1(s,CH₃), 18.25 (s,1H,OH). ¹³C NMR spectrum (CDCI₃): δ ppm 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6(C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5(C_{arom}+C_{coumarinic}), 160.4 (C₁). Anal. Calcd for C23H17O3N3: C, 72.052%; H, 4.469%, N, 10.960%, Found: C, 72.1%; H, 4.4%, N, 10.9%.

All 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivative 4 derivatives were evaluated for their antibacterial activity against four human pathogenic bacterial strains. These include *Escherichia coli (MTCC 40)*, *Klebsiella pneumoniae (MTCC 661)*, *Salmonella typhi (MTCC 733)* and *Shigella flexneri (MTCC 1457)*.



The nutrient agar was prepared and sterilized by autoclave. The sterile nutrient agar is cooled to 40° C, poured to the sterile petriplate and allowed to solidify. The nutrient agar was then inoculated with 10^{6} cfu/mL of respective microorganism using sterile spreader. Wells are made using sterile cork borer (8.5 mm) and compounds to be tested are added to each well with different concentrations ranging from 10 to 1000 μ g/mL. These were made from the stock solution of 4 mg/mL in dimethyl sulfoxide (DMSO). A 100 μ L volume of each dilution was introduced into wells (in duplicates) in the agar plates already seeded with bacterial suspension. These plates were incubated at 37°C for 24 h and observed for inhibition zones. Gentamicin was used as positive control.

Antioxidant activity

DPPH radical scavenging assay: The free radical scavenging activity for DPPH radicals wasperformed as described previously [22]. In brief, reaction mixture containing 200 μ L of 0.1 mM DPPH–ethanol solution, 90 μ L of 50 mM Tris–HCl buffer (pH 7.4) and 10 μ L of deionised water (as control) and various concentrations of compounds **4-a-f** (3.0 – 16.0 μ M), and ascorbic acid was used as a control. Reaction mixture was incubated for 30 min at room temperature and absorbance was read at 540 nm. The percentage radical scavenging activity was calculated according to the following formula: Inhibition (%) = [(Absorbance control-Absorbance sample)/Absorbance Control] X 100

Hydroxyl radical scavenging assay: The hydroxyl radical (OH) scavenging activity of newly synthesized compounds was determined previously [23]. We used Fe (III) - ascorbate – ethylenediaminetetraacetic acid – hydrogen peroxide system (Fenton's reaction) to generate hydroxyl radical. In brief, reaction mixture containing 0.01 mL of FeCl₃ (10 mM), 0.1 mL of EDTA (1 mM),0.36 mL of deoxyribose (10 mM), 0.1 ml of H_2O_2 (10 mM), 1 mL of the compounds **4a**-f(concentrations ranging from 3.0 – 16 .0 μ M), 0.33 mL of phosphate buffer (50 mM, pH 7.4) and 0.1 mL ascorbic acid (1 mM) was added. The mixture was incubated at 37^oC for 1 h and 1 mL of the incubated mixture was mixed with 1 mL of 10% trichloro acetic acid (TCA) and 1mL of thiobarbituric acid (TBA) (1% in 0.025 M NaOH), the resulting mixture was incubated in water bath at 90^oC for 20 min. The absorbance was measured at 532 nm. Ascorbic acid was used as a positive control. The percentage of hydroxyl radical scavenging activity was calculated using the formula: Inhibition (%) = [(Absorbance control-Absorbance sample)/Absorbance Control] X 100

Superoxide anion radical scavenging assay: The superoxide anion radical scavenging activity of newly synthesized compounds were determined previously [24]. 1 mL of Nicotinamide adenine dinucleotide (NADH) (468 μ M in 100 mM phosphate buffer of pH 7.4), 1 mLofNitro blue tetrazolium (NBT) (156 μ M NBT in 100 mM phosphate buffer of pH 7.4), and different concentration of compounds **4a-f** (3.0– 16.0 μ g/mL) were added to get the final volume of 3 mL. The reaction was started by the addition of 100 μ L of PMS (60 μ M in 100 mM phosphate buffer of pH 7.4). The mixture was incubated for 5 min at 25^oC and the absorbance was measured at 560 nm. Quercetin was used as a control. The percentage radical scavenging activity was calculated using the formula: Inhibition (%) = [(Absorbance Control-Absorbance sample)/Absorbance Control] X 100 .

Anti-inflammatory activity

Lipoxygenase inhibition assay: The lipoxygenase inhibition assay was performed according to the method previously described [25]. Briefly, to a solution of 0.1 mL of 0.2 M borate buffer (pH 9.0), 0.1 mL of 1000 units lipoxydase enzyme solution, test compounds **4a-f** dissolved in DMSO (3 - 16 µM) was added, agitated and incubated at room temperature for 5 min. Later, 2.0 mL of 0.6 mM linoleic acid was added and the absorbance was measured at 234 nm. Indomethacin was used as standard. The percent (%) inhibition was calculated by the following equation:


Inhibition (%) = [(Absorbance control-Absorbance sample)/Absorbance Control] X 100

Indirect haemolytic assay: Indirect haemolytic assay was performed according to the reported method [26]. One mL of fresh human red blood cells and 1 mL of fresh Hen's egg yolk in 8 mL of phosphate buffered saline was mixed to prepare the substrate for indirect hemolytic activity. One mL of this suspension was incubated with 4-28 μ g of partially purified venom for 45 min at 37^oC and 9 mL ice cold sodium perborate was used to stop the reaction. The reaction mixture was centrifuged at 2000 rpm for 20 min then the released hemoglobin was read at 540 nm. For inhibition studies 10 μ g of venom sample (secretory- PLA₂ purchased from sigma) was incubated with various concentrations of compounds **4a-f** (20-100 μ M in DMSO) for 30 min at room temperature and mixed with 1 mL of substrate solution and incubated at room temperature for 30 min. The reaction was stopped by adding 9 mL of ice cold sodium perborate and extent of hemolysis is measured at 540 nm. Aristolochic acid was used as reference drug. The percent (%) inhibition was calculated as follows: Inhibition (%) = [(Absorbance control-Absorbance sample)/Absorbance Control] X 100.

3. RESULTS AND DISCUSSION

In this investigation, a series of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** were designed, synthesized (**Schemes 1**) and biologically evaluated for their antibacterial , antioxidant activities and anti inflammaratory anti-inflammatory activity by indirect haemolytic and lipoxygenase were investigated. Thus, compound **3** was prepared by reaction of 4-hydroxycoumarine with POCl₃ in chloroform in the presence of acetic acid, The resulting compound **2** was then reacted with arylaldehydes in the presence of piperidine at reflux of CHCl₃ to give the (E) the coumarinic chalcones **3**, which precipitated from the hot MeOH solution after mixing **2** with the corresponding ArCHO . **Scheme 1**





i: POCl₃, ACOH, ii: CHCl₃, piperidine, Arylaldehyde

Compounds 3	R	Yield (%)
3a	Н	75
3b	F	80
3с	2,5 CH ₃	76
3d	OCH ₃	85
3e	NO ₂	75
3f	HC ₃	85
	Synthesis of compounds 2	

Synthesis of compounds 3

Compounds **3** were identified from analysis of their spectroscopic data. The infrared (IR) spectrum of compound **3d** showed the coumarin carbonyl groups at 1768 cm⁻¹ in addition to a broad band for the C=C group at 1595 cm⁻¹. The ¹H NMR spectrum showed *trans* olefinic protons H_a and H_b as *ortho*-coupled doublets at δ 8.25 (*J* = 15.6 Hz) and 6.92 (*J* = 15.9 Hz), respectively. The remaining aromatic protons of the aromatic aldehydes and the four protons of the coumarin moiety appeared as a multiplet in the region δ 7.25–8.08. The ¹³C{¹H} NMR spectrum of **3d** in DMSO-*d*₆ showed two downfield signals at δ 147.4ppm (C₄) and δ 162.4 ppm (lactone C=O) as well as an upfield signal to at δ 55.4 ppm (OCH₃).

The condensation of compounds **3** with malontrile in the presence of ammonium acetate at reflux of EtOH in one step afforded 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** in good yields . **Scheme 2**

	CH ₂ (CN) ₂ I ₃ COONH ₄ /EtOH/reflux	
Compounds 4	R	Yield (%)
4a	H	80
4b	F	75
4c	2,5 CH ₃	85
A -1	OCH ₃	75
4d	0	
40 4e	NO ₂	70

Scheme 2: Synthesis of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4

All new 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 were characterized by IR, 1H, 13C-NMR spectra as well as by NOESY and HMBC 2D-NMR experiments to elucidate their structures and completely assign the structural network of both protons and carbons. The spectral data were in accordance with the proposed structures (see Experimental Section).

The IR spectrum of **4d** showed a broad band at 3057 cm⁻¹ due to the presence of the NH_2 group, a strong band at 3316 cm⁻¹ was attributed for OH. Since chromone carbonyl groups usually appear as sharp absorption bands in the region 1620–1650 cm^{-1 27}, the band at 1680 cm⁻¹ was assigned to coumarin rather than the chromone carbonyl group.

Δr



In addition, the detection of a strong C=N stretching band at 1643 cm⁻¹ was indicative of the formation of the pyridine-3-carbonitriles ring. The ¹H NMR spectra of **4d** displays a signal at δ 3.75 ppm ascribable to the OCH₃ protons of the pyridine-3-carbonitriles ring. A characteristic singlet proton signal at δ 4.81 ppm was assigned to NH₂ protons. In addition, the aromatic protons (both coumarinic and aromatic) are observed between δ 6.40 and δ 8.20 ppm .

In the ¹³C NMR spectrum of **4d** indicated carbon atoms at δ 56.1(OCH₃), 97.6 (C₃); 109.5 (C₄); 122.6 (C₂); 151.9 (C₃); 153.7 (C₅), 162.1 (C₂), 168.2 (C₄), 114.1-129.5 (C_{arom}+ C_{coumarinic}), 160.4 (C₁).


The structure of **4d** was finally elucidated through the analysis of the ¹H, ¹³C HMBC spectrum which correlates the protons at δ 4.81 ppm with C_{5'} (δ 153.07 ppm) and C₄ (δ 109.5 ppm). The aromatic protons correlate with C_{3'} (δ 151.9 ppm).


Table 1

Correlations between HMBC and NOESY for compound 4d

Proton	HMBC	NOESY
H-n	H-n-C-j	H-n-H-j
OCH3	9', 10', 11'	H _{11',} H12'
H-5'	5',4'	
H-arom	3',4'	
ОН	4,3,2	

Similarly the spectral values for all the compounds and C, H, N analyses are given in the experimental part





The first reaction step consists of a nucleophilic attack on the unsaturated carbon, followed by intermolecular cyclization follow by a tautomeric enamine balance.



4. Pharmacology

Antibacterial activity

The synthesized 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4 a-f** were screened for *in vitro* antibacterial activity against four Gram Negative bacterial strains (*E. coli, K. Pnemoniae, S. typhi* and *S. Flexneri*) and the results are given in Table 2. All compounds except **4a** showed good zone of inhibition against pathogens *S. typhi* and *S. flexneri*. On the otherhand, all compounds displayed moderate activity against *E. coli*, but remained poor against *K. pnemoniae*. The compounds **4b,4f** with electron withdrawing groups on the phenyl ring showed good antibacterial activity. Whereas the compounds **4c** and **4f** with electron releasing groups on the phenyl ring showed moderate antibacterial activity on most of tested bacterial strains and 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivative **4d** without substitution on the phenyl ring showed least antibacterial activity. Also, all compounds except **4a** showed high potency against *S. typhi*. Thus, deactivating groups on phenyl ring enhances the antimicrobial behaviour of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives rather than the activating groups.

	Zone of inhibition in mm*				
Compound	Escherichia coli	Klebsiella pneumoniae	Salmonella typhi	Shigella flexneri	
4a	12	11	12	11	
4b	12	· · ·	21	23	
4c	12	· · ·	26	15	
4d	15	12	23	22	
4e	14	12	21	20	
4f	13	11	20	19	

 Table 2 Antibacterial activity of the 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives 4a-f

* Inhibition zones including cup borer (8.5 mm) diameter; Positive control zone is 35 to 40 mm; '-' = Not active

4. Antioxydant activity

We considered that it was worthwhile to study the potential aspects of these new 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** derivatives for antioxidant activity according to our initial planning. The synthesized compounds **4a-f** were tested for *in vitro* antioxidant activity by DPPH radical, hydroxyl radical and superoxide radical scavenging assays. The IC₅₀ values of the standards and test samples are summarized in Table 3. In all three antioxidant assays, Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives **4c,4f** bearing electron withdrawing groups on the phenyl ring showed antioxidant activities at 9.8 - 12.8 μ M concentration. But, 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivative **4b** and **4e** with electron releasing fluore group and nitro phenyl ring showed good antioxidant activity (7.0 - 8.8 μ M). Surprisingly, 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4a** without substitution on the phenyl ring is inactive in all antioxidant assays. Also, it should be noted that it is not possible to give any rational explanation for antioxidant activities even in the absence of essential enolic group.

Table 3 IC₅₀ values of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 in anti-oxidant assays

		IC ₅₀ values in µM	
Compounds	DPPH radical scavenging assay	Hydroxy radical Scavenging assay	Superoxide radical scavenging assay
4a	NA	NA	NA
4b	12.4	12.8	9.8
4c	11.1	11.0	12.7
4d	11.2	11.2	11.8
4e	11.1	11.0	11.5
4f	11.0	10.8	11.4
Ascorbic acid	3.8	3.9	-
Quercetin	-	-	4.9



Anti-inflammatory activity

As per our objective, we next examined the anti-inflammatory activities of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives **4a-f** by lipoxygenase inhibition and phospholipase A_2 (PLA₂) inhibition assays. The IC₅₀ values of the standards and test samples in both assays are given Table 4. In both the assays, 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives **4b** and **4c** bearing strong electron withdrawing nitro groups showed potent anti-inflammatory activity in lipoxygenase inhibition assay (5.0 – 5.1 µM) and PLA₂ inhibition assay (26.5 - 34.9 µM). While, the other derivatives substituted with weak deactivating (**4b-e**). Notably, compound **4a** with no substitution on phenyl ring is not active. It should be noted that, **4b** and **4c** nearly have anti-inflammatory activities, as that of standards Indomethacin and Aristolochic acid. Thus, 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** derivatives with strong deactivating groups are more potent than 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles **4** derivatives with weak deactivating groups .

Table 4. IC₅₀ values of 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 for anti-inflammatory activity

Compounds	IC_{50} values in μM		
	Lipoxygenase inhibition assay	PLA ₂ inhibition assay	
4a	NA	NA	
4b	5.0	26.5	
4c	5.1	34.9	
4d	11.4	61.1	
4e	11.3	61.4	
4f	11.1	61.8	
Indomethacin	4.8		
Aristolochic acid		25.0	

CONCLUSIONS

In summary, we have synthesized a new 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 derivatives and examined their antimicrobial, antioxidant and anti-inflammatory activities. The synthesized compounds showed moderate *in vitro* antibacterial activity. 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 derivatives are good antibacterial agents than the 4-Alkyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles 4 derivatives. On contrary, in all the anti-oxidant assays, 4-Aryl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives are poor antioxidants compared to 4-Alkyl-2-amino-6-(4-hydroxy coumarin-3-yl) pyridine-3-carbonitriles derivatives. Also, aryl derivatives bearing deactivating groups are less anti-oxidant properties than those bearing activating groups. But, it is not possible to give any explanation for the antioxidant activities of these compounds even in the absence of essential enolic group.

Acknowledgment

We are indebted to the Professor Antonio Romerosa, University of Almeria, Spain, for providing facilities to carry out the analysis described in this paper and for the activities tests. We also thank the staff of the Chemistry department, College of Science and Arts, Al-Rass, Qassim University, Saoudi Arabia (KSA) for help and fruitful discussions

REFERENCES

- [1] Z M Nofal, M El-Zahar, S Abd El-Karim. Novel coumarin derivatives with expected biological activity. *Molecules*. **2000**, 5, 99–113.
- [2] K R Reddy, R Mamatha, M S Surendra Babu, Shiva Kumar K. Synthesis and antimicrobial activities of some triazole, thiadiazole, and oxadiazole substituted coumarins. *Journal of Heterocyclic Chemistry*. **2014**, 51(1), 132–137.
- [3] W Q Gao, Q Y Li, J Chen, Z C Wang, C.L Hua. Total synthesis of six 3,4-unsubstituted coumarins. *Molecules*.2013, 18, 15613–15623.
- [4] M Purushothaman, K Loganathan, K M S Ali, Joseph A Selvin. An efficient and facile synthesis of coumarin derivatives as potent antimicrobial agents. *International Journal of Chem Tech Research*. **2014**, 6 (1), 538-546.
- [5] M S El-Gendy, A Abdel-Aziem, A O Abdelhamid. Reactions and antimicrobial activity of (3-(3-(4-Methoxyphenyl)acryloyl)-2H-Chromen-2-one. International Journal of Advanced Research. **2013**, 1(10), 557-568.



- [6] A Pangal, G Muiz, M Yusufi, G Devasthale, E Khan. In vitro investigation of antibacterial activity of novel 3acetylcoumarin schiff bases and their molecular docking studies. International Journal for Pharmaceutical Research Scholars 2014, 3 (1), 696-703.
- [7] X Niu, W Xing, W Li, T Fan, H Hu, Y Li. Isofraxidin exhibited anti-inflammatory effects *in vivo* and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages *in vitro* via the MAPK pathway. *Int. Immunopharmacol.* 2012, 14, 164–171.
- [8] M Alipour, M Khoobi, S Emami, S Fallah-Benakohal, S F Ghasemi-Niri, M Abdollahi, A Foroumadi, A Shafiee. Antinociceptive properties of new coumarin derivatives bearing substituted 3, 4-dihydro-2*H*-benzothiazines. DARU Journal of Pharmaceutical Sciences.2014, 22: 9-17.
- [9] F A Jiménez-Orozco, A A R Rosales, A Vega-López, M L Domínguez-López, M. J García- Mondragón, A Maldonado-Espinoza, C Lemini, N Mendoza-Patiño, J J Mandoki. Differential effects of esculetin and daphnetin on *in vitro* cell proliferation and in *vivo* estrogenicity. *Eur. J. Pharmacol.* 2011, 668, 35–41.
- [10] W Liu, J Hua, J Zhou, H Zhang, H Zhu, Y Cheng, R Gust, . Synthesis and *in vitro* antitumor activity of novel scopoletin derivatives. *Bioorg. Med. Chem. Lett.* **2012**, 22, 5008–5012.
- [11] S C Tsay, J R Hwu, R Singha, W C Huang, Y H Chang, M H Hsu, F.K Shieh, C C Lin, K C Hwang, J C Horng, et al. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. Eur. J. Med. Chem. 2013, 63, 290–293.
- [12] J R Hwu, S Y Lin, S C Tsay, E de Clercq, P Leyssen, J Neyts.Coumarin–purine ribofuranoside conjugates as new agents against hepatitis C virus. *J. Med. Chem.*2011, 54, 2114–2126.
- [13] B Sarkanj, M Molnar, M Cacic, L Gille. 4-Methyl-7-hydroxycoumarin antifungal and antioxidant activity enhancement by substitution with thiosemicarbazide and thiazolidinone moieties. *Food Chem.* **2013**, 139, 488–495.
- [14] A A Farghaly, P Vanelle, H S El-Kashef. Synthesis, reactions and antimicrobial activity of some new 1,3,4oxadiazoles, 1,2,4-triazoles and 1,3,4-thiadiazines derived from pyrazole. *Heterocyclic Commun.* 2005, 11 (3-4), 255–262.
- [15] K Shubakar, K K B Umesha, N Srikantamurthy, J Chethan. Synthesis and antimicrobial evaluation of novel derivatives of 1,3,4-thiadiazine incorporated with pyrazole-4-carboxylic acid moiety. *Bulgarian Chemical Commun.* 2013, 45 (3), 274 – 279.
- [16] T M Abdel-Rahman, Synthesis, reactions, and anticancer activity of some 1,3,4- thiadiazole/thiadiazine derivatives of carbazole. *Phosphorus, Sulfur, and Silicon and the Related Elements*. **2006**, 181 (8), 1737-1754.
- [17] M Cacic, V Pavic, M Molnar, B Šarkanj and E Has-Schön. Design and synthesis of some new 1,3,4-thiadiazines with coumarin moieties and their antioxidative and antifungal activities. *Molecules*. **2014**, 19, 1163-1177.
- [18] A O Abdelhamid, Z H Ismail, S M Abdel-Gawad, M M Ghorab, A Abdel-Aziem. synthesis of some New Thieno[2,3b]pyridines, Pyrimidino[4,5:4,5]thieno[2,3-b]-pyridines, and 2,3-Dihydro-1,3,4-thiadiazoles. *Phosphorus, Sulfur, Silicon, and Related element.* **2009**,184, 58–75.
- [19] H K Kallur, S Prabhudev, Mathapati, Kishore Singh Chatrapati, Siddanna. A. Durgad, R. C Hariprasanna, Mohammad Younus.Synthesis and antimicrobial activity of some 1, 3, 4-thiadiazole derivatives. Am. J. PharmTech Res. 2012, 2 (5) 680-693.
- [20] A S Nayak, and N V Madhav. Rabid synthesis and antimicrobial activity of some 2-amino-5-alkyl/aryl-1, 3, 4-thiadiazoles. Acta Chim. Pharm. Indica. 2014, 4 (1), 63-67.
- [21] D E Abdel Rahman and K O Mohamed. Synthesis of novel 1,3,4-thiadiazole analogues with expected anticancer activity. *Der Pharma Chemica*. **2014**, 6 (1), 323-335
- [22] Chuanga, Y. M. D.; Wanga, Y.S.; Kuob, Y. Y.; Tsaia, H. P.; Shyura, W. L. Metabolite profiling and chemopreventive bioactivity of plant extracts from *Bidens pilosa*. J. Ethnopharmacol., 2004, 95, 409–419.
- [23] Halliwell, B.; Gutteridge, J. M. C.; Arnoma, O. L. The deoxyribose method: A simple "test-tube" assay for determination of rate constants for reactions of hydroxyl radicals. *Anal. Biochem.*, **1987**, *165*, 215-219.
- [24] Nishimiki, M. N.; Appaji.; Yagi, K. Protein synthesis in rabbit reticulocytes: Characteristics of peptide chain initiation factors. *Biochem. Biophys. Commun.*, **1972**, *46*, 849-854.
- [25] Shinde, U. A.; Kulkarni, K. R.; Phadke, A. S.; Nair, A. M.; Mungantiwar, D. V. J.; Saraf, M. N. Mast cell stabilizing and lipoxygenase inhibitory activity of Cedrus deodara (Roxb.) Loud. wood oil. *Ind. J. Exp. Biol.*, **1999**, 371, 258-261.
- [26] Boman, H. G.; Kaletta, U. Chromatography of rattlesnake venom A separation of three phosphodiesterases. *Biochem. Biophys. Acta.*, **1957**, *24*, 619–623.
- [27] Ahn, K. H.; Kim, H.; Kim, J. R.; Jeomg, S. C.; Kang, T. S.; Shin, H. T.; Lim, G. J. New Synthetic process of Lansoprazole. Bull. Korean Chem. Soc., 2002, 23, 626-628.